MEPE loss-of-function variant associates with decreased bone mineral density and increased fracture risk

Ida Surakka, Lars G. Fritsche, Wei Zhou, Joshua Backman, Jack A. Kosmicki, Haocheng Lu, Ben Brumpton, Jonas B. Nielsen, Maiken E. Gabrielsen, Anne Heidi Skogholt, Brooke N. Wolford, Sarah E. Graham, Y. Eugene Chen, Seunggeun Lee, Hyun Min Kang, Arnulf Langhammer, Siri Forsmo, Bjørn Olav Åsvold, Unnur Styrkársdóttir, Hilma Hólm, Daníel F. Guðbjartsson, Kāri Stefánsson, Aris Baras, Xiaodong Bai, Suganthi Balasubramanian, Leland Barnard, Andrew Blumenfeld, Michael Cantor, Giovanni Coppola, Aris N. Economides, Gisu Eom, Lukas Habegger, Young S. Hahn, Alicia Hawes, Marcus B. Jones, Shareef Khalid, Luca A. Lotta, Evan K. Maxwell, Lyndon J. Mitnaul, John D. Overton, Jeffrey G. Reid, Manuel Allen Revez Ferreira, William Salerno, Deepika Sharma, Alan R. Shuldiner, Jeffrey Staples, Ashish Yadav, Gonçalo R. Abecasis, Kristian Hveem, Cristen J. WillerNature Communications 2020 · DOI

TL;DR

This study identified a rare loss-of-function (LoF) mutation in the MEPE gene that significantly decreases bone mineral density (BMD) and increases the risk of osteoporosis and fractures. This finding highlights the clinical relevance of high-impact, rare genetic variants for precision medicine, potentially enabling early intervention to prevent bone-related diseases.

What Problem Does This Paper Address?

Genetic association studies have identified numerous variants linked to complex traits like bone mineral density (BMD). However, a significant challenge is that most of these associated variants reside in non-coding regions of the genome, making their functional interpretation and direct causal link to disease difficult to establish. While common variants are well-studied, rare, high-impact variants, particularly loss-of-function (LoF) mutations, are often missed by standard genotyping arrays and may play a crucial role in disease etiology. This paper aims to address this gap by specifically searching for LoF mutations associated with BMD and fracture risk, moving beyond the limitations of studying only common variants or non-coding regions. Understanding these rare variants could unlock new avenues for precision medicine, allowing for targeted interventions based on an individual's genetic predisposition.

Methods

The researchers employed a multi-stage approach combining low-pass whole genome sequencing, imputation, and large-scale genome-wide association studies (GWAS).

  1. Discovery Cohort Enrichment: They enriched their discovery cohort (Nord-Trøndelag Health Study - HUNT) for loss-of-function (LoF) mutations by performing low-pass whole genome sequencing on a subset of participants.
  2. Imputation: Variants, including insertion/deletion polymorphisms (indels), were then imputed into the remaining HUNT samples. This allowed them to analyze a much larger set of variants than would be possible with direct genotyping alone.
  3. GWAS: They conducted a GWAS for ultradistal forearm BMD in the imputed HUNT dataset (N=19,705).
  4. Replication: Promising, previously unreported variants were then replicated in two large independent cohorts: the UK Biobank (N=279,435) and Icelandic samples (N=375,984).
  5. Phenome-Wide Association Study (PheWAS): For the identified MEPE LoF variant, they performed a PheWAS to assess its association with various bone-related clinical endpoints, including different types of fractures and osteoporosis.

This approach is novel in its specific enrichment for LoF variants through sequencing and imputation, allowing for the discovery of rare but potentially highly impactful genetic factors.

Datasets

  • HUNT (Nord-Trøndelag Health Study): The discovery dataset, a population-based cohort from Norway.
  • Genotyping: Illumina Human CoreExome v1.1 array.
  • Sequencing: Low-pass whole genome sequencing on a subset (N=2202).
  • Imputation: Using Haplotype Reference Consortium and a population-specific panel.
  • BMD measurements: Ultradistal forearm BMD (SXA).
  • Clinical data: Fracture and osteoporosis diagnoses from hospital registries.
  • Total discovery sample size for BMD analysis: N=19,705.
  • Total sample size for PheWAS: N=69,716.
  • UK Biobank: A large replication cohort.
  • Exome sequencing data available for a substantial number of participants.
  • BMD measurements: Heel bone estimated BMD (eBMD) and other sites.
  • Clinical data: Fracture information.
  • Replication sample size: N=279,435.
  • Icelandic Samples (deCODE genetics): Another large replication cohort.
  • Genotyped and imputed using a whole-genome sequenced population-specific panel.
  • BMD measurements: Lumbar spine, hip, arm, and whole body BMD (DXA).
  • Clinical data: Health-care registry data for endpoints.
  • Replication sample size: N=375,984.

Key Insights and Ideas

  • Rare LoF variants can have large effects: The study strongly suggests that rare, high-impact LoF variants, often overlooked in traditional GWAS, can have a more profound effect on complex traits like BMD than common variants.
  • MEPE's crucial role in bone development: The identification of a MEPE LoF mutation as a significant determinant of BMD and fracture risk highlights the gene's critical function in bone metabolism, potentially during peak bone mass acquisition.
  • Precision medicine implications: The lifelong effect of the MEPE LoF variant on BMD means that identifying carriers early in life could allow for preventative treatments to maximize peak bone mass and reduce future fracture risk.
  • Cosmopolitan panels may miss clinically relevant variants: The finding that this high-impact variant was not present in common cosmopolitan panels underscores the need for more diverse and comprehensive genetic databases to capture clinically relevant functional variants.

Key Results

  • A novel loss-of-function (LoF) mutation in the MEPE gene, p.(Lys70IlefsTer26), with a minor allele frequency (MAF) of 0.8% in the HUNT cohort, was identified.
  • This MEPE LoF variant was strongly associated with decreased ultradistal forearm BMD (P-value = 2.1 × 10<sup>-18</sup>) in the HUNT discovery cohort.
  • The variant was also significantly associated with an increased risk of osteoporosis (P-value = 4.2 × 10<sup>-5</sup>) and fractures (P-value = 1.6 × 10<sup>-5</sup>) in the HUNT cohort.
  • These associations were replicated in the UK Biobank (eBMD P-value = 1.2 × 10<sup>-16</sup>) and Icelandic samples (forearm fracture P-value = 0.005), although the lower MAF in these populations limited replication power for some phenotypes.
  • The effect size of the MEPE LoF variant on BMD was substantial, approximately eight times larger than that of common variants previously associated with BMD at the same locus.
  • Carriers of the MEPE LoF mutation showed a similar rate of BMD loss with age compared to non-carriers, suggesting the variant primarily affects peak bone mass rather than the rate of bone loss later in life.
  • The MEPE LoF mutation identified carriers at a higher rate (1.54%) than individuals with low BMD (< -2.5 SD, 0.62%), suggesting it could be a more sensitive indicator for individuals at risk.

Limitations and Future Work

  • Phenotype Heterogeneity: The study acknowledges differences in BMD measurement methods (SXA vs. DXA vs. ultrasound) and fracture ascertainment across the discovery and replication datasets. While correlations between effect estimates were generally high, this heterogeneity could impact replication power.
  • Limited Fracture Data in Replication: While associations with BMD were robustly replicated, the replication for fracture risk was less consistent across all datasets, partly due to lower MAF and potentially different fracture ascertainment.
  • Incomplete Catalog of LoF Variants: The study focused on a specific MEPE LoF variant. The authors note that other LoF mutations in MEPE may exist in different populations, and a more comprehensive catalog of LoF variants is needed.
  • Future Work: The authors suggest that screening for MEPE LoF mutations before adulthood could be a valuable tool for precision medicine, enabling early intervention to optimize peak bone mass and prevent osteoporosis and fractures. They also propose that continued investigation of rare variants through sequencing is crucial for identifying genes with immediate clinical utility.

Summary updated

Abstract

A major challenge in genetic association studies is that most associated variants fall in the non-coding part of the human genome. We searched for variants associated with bone mineral density (BMD) after enriching the discovery cohort for loss-of-function (LoF) mutations by sequencing a subset of the Nord-Trøndelag Health Study, followed by imputation in the remaining sample (N = 19,705), and identified ten known BMD loci. However, one previously unreported variant, LoF mutation in MEPE, p.(Lys70IlefsTer26, minor allele frequency [MAF] = 0.8%), was associated with decreased ultradistal forearm BMD (P-value = 2.1 × 10<sup>-18</sup>), and increased osteoporosis (P-value = 4.2 × 10<sup>-5</sup>) and fracture risk (P-value = 1.6 × 10<sup>-5</sup>). The MEPE LoF association with BMD and fractures was further evaluated in 279,435 UK (MAF = 0.05%, heel bone estimated BMD P-value = 1.2 × 10<sup>-16</sup>, any fracture P-value = 0.05) and 375,984 Icelandic samples (MAF = 0.03%, arm BMD P-value = 0.12, forearm fracture P-value = 0.005). Screening for the MEPE LoF mutations before adulthood could potentially prevent osteoporosis and fractures due to the lifelong effect on BMD observed in the study. A key implication for precision medicine is that high-impact functional variants missing from the publicly available cosmopolitan panels could be clinically more relevant than polygenic risk scores.
BibTeX
@inproceedings{surakka2020mepe,
  author = {Ida Surakka and Lars G. Fritsche and Wei Zhou and Joshua Backman and Jack A. Kosmicki and Haocheng Lu and Ben Brumpton and Jonas B. Nielsen and Maiken E. Gabrielsen and Anne Heidi Skogholt and Brooke N. Wolford and Sarah E. Graham and Y. Eugene Chen and Seunggeun Lee and Hyun Min Kang and Arnulf Langhammer and Siri Forsmo and Bjørn Olav Åsvold and Unnur Styrkársdóttir and Hilma Hólm and Daníel F. Guðbjartsson and Kāri Stefánsson and Aris Baras and Xiaodong Bai and Suganthi Balasubramanian and Leland Barnard and Andrew Blumenfeld and Michael Cantor and Giovanni Coppola and Aris N. Economides and Gisu Eom and Lukas Habegger and Young S. Hahn and Alicia Hawes and Marcus B. Jones and Shareef Khalid and Luca A. Lotta and Evan K. Maxwell and Lyndon J. Mitnaul and John D. Overton and Jeffrey G. Reid and Manuel Allen Revez Ferreira and William Salerno and Deepika Sharma and Alan R. Shuldiner and Jeffrey Staples and Ashish Yadav and Gonçalo R. Abecasis and Kristian Hveem and Cristen J. Willer},
  title = {{MEPE loss-of-function variant associates with decreased bone mineral density and increased fracture risk}},
  booktitle = {Nature Communications},
  year = {2020},
  doi = {10.1038/s41467-020-17315-0},
}
Figure